Tradestie Institutional Equity Comparison Engine

NVCT vs ICCC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while NVCT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, NVCT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ICCC at N/M Forward P/E and 15.2% operating margin (+11.5% YoY). In options structure, NVCT sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro) against ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ICCC
NVCT N/M vs ICCC N/M Fwd P/E
Growth & Margin Winner ICCC
Op Margin 0.0% vs 15.2% ยท YoY +0.0% vs +11.5%
Momentum & Technical Winner NVCT
1Y +222.8% vs +88.8% ยท 52W Pos 57% vs 91%
Options & Structure Winner NVCT
BREAKDOWN (9th %ile IV) vs UNCLASSIFIED (N/A IV)
NVCT NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.11
-5.58% 1D
Market Cap $696.0M
1M Return +2.74%
1Y Return +222.8%
Forward P/E N/M
Unified AI Score
50.5 / 100 HOLD
Tech 47.0 Fund 57.0 Flow 71.0 Mom 54.0
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NVCT +222.8% ICCC +88.76% Spread: +134.04 pp (NVCT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NVCT TTM Op. Margin: 0.0% ICCC TTM Op. Margin: 15.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVCT vs ICCC. Trailing 12-month operating profitability (NVCT 0.0% vs ICCC 15.2%) and valuation multiples (NVCT N/M vs ICCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NVCT (2) vs ICCC (7)
Institutional Metric NVCT ICCC Criterion Row Winner
Market Capitalization Scale $696.0M $97.7M Larger Scale NVCT
Trailing P/E Ratio Valuation N/M 56.6x Lower Multiple ICCC
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +11.5% Higher Growth ICCC
Operating Margin (TTM) Profitability 0.0% 15.2% Higher Margin ICCC
Net Profit Margin Profitability 0.0% 2.6% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency -67.0% 2.6% Higher ROE ICCC
52-Week Range Position Momentum 57% ($6โ€“$29) 91% ($5โ€“$12) Stronger Trend ICCC
Beta / 30D Volatility Risk Regime 0.71ฮฒ ยท 85% Vol 0.24ฮฒ ยท 46% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 50.5 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite NVCT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NVCT vs ICCC Buy Guide
NVCT BREAKDOWN
98d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live NVCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NVCT nor ICCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.